Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Transdermal Drug Delivery Systems01:18

Transdermal Drug Delivery Systems

Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
Drug Delivery: Miscellaneous Routes01:22

Drug Delivery: Miscellaneous Routes

Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection,  and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Intrauterine Drug Delivery Systems01:21

Intrauterine Drug Delivery Systems

Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
Drug Delivery: Overview01:16

Drug Delivery: Overview

The selection of a drug's delivery route depends upon its physicochemical properties, including lipid or water solubility and ionization, as well as the therapeutic requirement, such as immediate or sustained effect. These routes can be divided into three primary categories: enteral, parenteral, and topical.
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the gastrointestinal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nocturia in postmenopausal women.

Menopause (New York, N.Y.)·2026
Same author

A Contemporary View of Menopausal Hormone Therapy: Correction.

Obstetrics and gynecology·2026
Same author

Quantification of "Mercy Sex" in Heterosexual Women.

Journal of sex & marital therapy·2026
Same author

Report of the FDA's expert panel on hormone therapy.

Menopause (New York, N.Y.)·2026
Same author

Tailoring transdermal estradiol dose to maximize benefits and minimize risks.

Menopause (New York, N.Y.)·2026
Same author

Safety of 48 months of elagolix with add-back therapy for endometriosis-associated pain.

AJOG global reports·2026
Same journal

Dual PLGA nanoparticles co-encapsulating P5091 and Resveratrol synergistically target the USP7-MDM2-P53 axis for glioma therapy.

Nanomedicine : nanotechnology, biology, and medicine·2026
Same journal

Regenerative polymer-based modalities for diabetic foot ulcers: From material design to clinical translation.

Nanomedicine : nanotechnology, biology, and medicine·2026
Same journal

Mentha-derived green synthesized ZnO nanoparticles potentiate methotrexate induced molecular and migratory inhibition via gene expression modulation in T24 bladder cancer cells.

Nanomedicine : nanotechnology, biology, and medicine·2026
Same journal

Fluvastatin-loaded chitosan-coated transfersomes for tumor-targeted nanotheranostics: Optimization, in-vitro cytotoxicity, and in-vivo radiokinetic evaluation.

Nanomedicine : nanotechnology, biology, and medicine·2026
Same journal

Nanostructured lipid carriers of lutein-based dissolving microneedle patch: A promising approach for the management of rheumatoid arthritis.

Nanomedicine : nanotechnology, biology, and medicine·2026
Same journal

Surface-charge-engineered magnetic silk fibroin nanocarriers for pH-responsive 5-fluorouracil delivery and in vitro magnetic localization.

Nanomedicine : nanotechnology, biology, and medicine·2026
See all related articles

Related Experiment Video

Updated: May 22, 2026

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier
10:16

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Published on: February 8, 2017

Nanoparticle delivery for transdermal HRT.

Pilar Valenzuela1, James A Simon

  • 1Department of Obstetrics and Gynecology, Pontificia Universidad Católica de Chile, School of Medicine, Santiago, Chile. pvalenzu@uc.cl

Nanomedicine : Nanotechnology, Biology, and Medicine
|May 30, 2012
PubMed
Summary
This summary is machine-generated.

Nanoparticle drug delivery offers advantages for transdermal hormone therapy. Micellar nanoparticle estradiol emulsion (MNPEE) provides effective, safe estrogen therapy for menopausal symptoms with minimal skin irritation.

More Related Videos

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

Related Experiment Videos

Last Updated: May 22, 2026

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier
10:16

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Published on: February 8, 2017

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

Area of Science:

  • Nanomedicine
  • Drug Delivery Systems
  • Dermatology

Background:

  • Transdermal drug delivery bypasses first-pass hepatic metabolism, offering advantages over oral administration.
  • Nanoparticles possess unique properties facilitating direct skin transport of substances.
  • Estrogen therapy is crucial for managing menopausal symptoms, with transdermal routes preferred to avoid hepatic metabolism.

Purpose of the Study:

  • To review nanoparticle delivery systems for transdermal administration.
  • To discuss the application of nanoparticle technology in transdermal hormone therapy, specifically estrogen therapy.
  • To evaluate Micellar Nanoparticle Estradiol Emulsion (MNPEE) as a novel transdermal delivery system.

Main Methods:

  • Review of existing literature on nanoparticle transdermal delivery.
  • Analysis of clinical trial data for MNPEE in managing menopausal vasomotor symptoms.
  • Assessment of safety and efficacy data, including adverse effects and transference studies.

Main Results:

  • MNPEE demonstrates efficacy in managing moderate to severe vasomotor symptoms, comparable to placebo in clinical trials.
  • This nanoparticle emulsion offers stable plasma estradiol concentrations and infrequent skin-related adverse effects.
  • Transference of estradiol to male partners was minimal and within physiological ranges.

Conclusions:

  • MNPEE is a safe and effective transdermal estrogen therapy for postmenopausal women.
  • It represents a significant advancement in nanomedicine for hormone replacement therapy.
  • The system avoids permeation enhancers, reducing potential skin irritation compared to other transdermal methods.